
10XBIO
Biotech Catalyzed
Innovations in Body Contouring

Overview & Company Highlights

- **Dermatology company developing a next generation adipolytic drug product (10XB101) for body contouring**
  - Superior efficacy, better tolerability, larger treatment areas than current marketed product Kybella
- **Phase 2b study demonstrates far superior efficacy and tolerability relative to Kybella indicating a paradigm shift for pharmaceutical body contouring**
  - ITT: 62% of 10XB101 patients achieve ≥ grade 2 improvement on FDA primary endpoint vs. 16% for Kybella
    - Completer Population (as defined, slide 8) achieved 80% grade 2 improvement in FDA primary endpoint
  - >50% reduction in key market acceptance tolerability side effects: bruising, edema, and pain
- **Phase 3 ready sub-mental indication in 2024 with reduced development risk, time, and cost**
  - Novel formulation of polidocanol, long history safety, being developed under 505(b)2 pathway
- **Hugel, Inc., a leading aesthetic dermatology company in South Korea, licensing partner in Korea and China territories**
- **Strong intellectual property position**
  - 25 issued patents covering formulation and method of use US, EU, CA, AU, JP, KR, CN.
- **Experienced leadership by dermatology industry veterans**
  - John Dobak, MD – past CEO, DermTech, Inc. (NASDAQ: DMTK); Dan Piacquadio, MD – CEO, Therapeutics, Inc.

Adipolysis Destroys Fat Tissue For Long Lasting Results

Mechanism Of Action

- Drug volume injected based on defined pattern
- Detergent lyses cell membranes
- Destroyed fat cells absorbed by the body
- Mild fibrosis firms and tightens the submental area



Injection procedure



Clinical Value Proposition of 10XB-101

Superior efficacy and tolerability relative to Kybella

Demonstrates much higher 2 grade or more improvement in appearance desired by patients.

Demonstrates reduced edema, bruising, pain, etc. Does not require local anesthetic, ice packs, nor chin straps



Expands treatment areas to other body sites that require larger injection volumes to treat larger fat volumes

Up to 20 CC of high concentration drug product injected into abdominal fat without significant tolerability or adverse events.

May shorten treatment interval and time to desired aesthetic effect

Due to injection site reactions, real-world treatment interval for Kybella is 2-3 months with up to 12-months to complete a full treatment course

Body Contouring Opportunities (Patients per Body Region)

Submentum
3.0MM

Inner Thighs
5.0MM

Outer Thighs
4.0MM



Buttocks
4.0MM

Arms
4.0MM



Abdomen/Flanks
12.0MM

Gynecomastia
0.5MM

Total U.S. Potential Patients
32.5MM

Zeltiq-Source: Rabin Research Report, interview of 1,076 US men and women

Submental Fat Market Opportunity (SMF)

SMF Frequent Cosmetic Concern of High Importance

- Significant concern for 68% of patients
- Treatment improves self-confidence, patient feel younger and less self-conscious
- U.S. dermatologists and plastics surgeons see 10-11 patient/mo. for SMF concerns

Percentage of Population Somewhat to Extremely Bothered by . . .

- 89% Excess Weight on Any Part of the Body
- 71% Lines and Wrinkles Around the Eyes
- 75% Skin Texture and/or Discoloration
- **68% Excess Fat Under the Chin**
- 65% Lines, Wrinkles and/or Folds in the Mid-Face Around the Cheeks and Mouth
- 63% Sagging Facial Skin
- 56% Lines and Wrinkles in the Forehead Area
- 55% Lines and Wrinkles Between My Eyebrows
- 41% Hair Loss
- 26% Acne Scars

Source: 2014 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures.

Submentum

3.0MM Patients in U.S.

10XBIO

Product-Market Fit

Current Treatments Do Not Address Unmet Needs for Submental Fat Treatment

- Poor efficacy
- Unpredictable results
- Prolonged treatment time
- Prolonged recovery and adverse side effects
- Poor provider economics
- High-cost relative to benefit

Ideal Product Profile

- High efficacy- grade 2 or greater SMF improvement
- Minimal down time and adverse events
  - Patients to resume normal activities within 1-3 days
- Results achieved in 3-5 months
- Multiple treatments preferred by physicians
  - Ability to better tailor results
  - Better economics
  - Inability to correct undesirable result if therapy too aggressive
- Patients prefer fewest treatments possible
  - Okay with multiple treatments if downtime and adverse effects are limited

10XBIO

LEK Market Assessment, 2016

Kybella Adoption Hampered by Product Profile

Low Efficacy
- Only 16% patients on average achieve 2-grade improvement

Poor Tolerability
- Significant swelling that can last 30 days
- Bruising
- Injection pain likened to bee sting

Local Anesthesia Injection Pre-treatment
- Added procedure time and additional patient injections

Extended Treatment Period
- Can take 1-year to achieved desired results

Limited Injection Volume
- 10 ml total injection volume and side-effects limits use in other body area indications, larger volumes cause more side effects

High-cost relative to benefit
- Estimated cost $3,000 - $6,000, with inferior results





10XB101 Phase 2b Repeat Treatment Study

- **Treatment Regimen**
  - Single treatment, up to 50 injections, 0.2 ml/injection
  - 4 dose cohorts, n=13/cohort, 3 active/1 placebo, (1:1:1:1)
  - Treatment: up to a maximum of 6 treatments 4 weeks apart at Visit 2, 3, 4, 5, 6 and 7
- **Endpoints**
  - Clinician and patient submental fat grading
    - **CSFS** (Clinician Submental Fat Score) & **PSFS** (Patient Submental Fat Score): 0-4 point scale
    - FDA Composite Endpoint: **CSFS & PSFS both ≥ 2**
  - Local skin reactions (0 (none), 1 (mild), 2 (moderate), 3 (severe))
    - Erythema, edema, tenderness on palpation, bruising, pain, burning/stinging
  - Safety labs, ECG
- **Analysis Populations**
  - Intent-to-Treat (ITT)
    - Includes all enrolled subjects who received any injections of test article
  - Completer Population
    - Includes a subset of the ITT Population who meet the following criteria:
      - Had at least 4 treatments or completed treatments per protocol (I.e., treatments did not continue once CSFS=0)
      - Completed the 12 weeks after final treatment assessments
      - Did not have any significant protocol deviations that would impact the evaluation of efficacy

10xB101 Phase 2b Data Highlights

- 10XB101 ITT analysis best dose shows ~4-fold increase in ≥ 2-grade improvement in composite FDA endpoint relative to Kybella (62% vs. 16%)
- 80% of Completer Population achieved a 2-grade improvement in composite endpoint
  - A meaningful proportion of completers achieve 3-grade improvement (10%-33%)
- More rapid onset of efficacy than Kybella
  - On average patients achieve 1-grade improvement after 2 treatments
  - ~50% of patients can achieve a 2-grade improvement after 3-4 treatments
- >50% reduction in key tolerability side effects that impact product adoption: bruising, edema, pain, induration, nodules, numbness
  - Superior tolerability may allow for shorter treatment intervals

10XB101 FDA Defined Post-Treatment Success Markedly Exceeds Kybella

(ITT Population, Composite CSFS & PSFS ≥ 2, Visit 8, 4 weeks after Final Treatment)



**average Refine 1 & 2 trials

Fisher Exact Test, * Statistical Sig.

10XB101 Patient and Clinician Submental Grading ≥ 2 Change from Baseline Tops Kybella

(ITT Population, Best Dose, PSFS & CSFS, Visit 8, 4 weeks after Final Treatment)

Meaningfully higher rates of Patient Reported (PR) and Clinician Reported (CR) Submental Fat Assessment Change from Baseline of ≥ 2

	10XB101	Kybella*
PR ≥ 1	85%	80%
CR ≥ 1	77%	80%
PR ≥ 2	**77%**	18%
CR ≥ 2	**62%**	22%

.... 10XB101 Demonstrates ~4x .... Greater Improvement

*Average proportion from Refine 1 & 2 trials at week 12

10XB101 Shows >2-Fold Increase in Mean CSFS Change at Same Time Point Versus Kybella (ITT Analysis)

Kybella Phase 2b Data*



10XB101 Phase 2b Data



*Kythera S-1 registration statement, Phase 2b study, sec.gov

*One-way ANOVA

Phase 2b: Tolerability Outcomes

Blinded data reflects outcomes in aggregate for all treatment cohorts (3 active/1 placebo, 1:1:1:1)

10XB101 has meaningfully lower Injection Site Reaction Adverse Events compared to Kybella, including: edema, pain, bruising, induration, anesthesia, nodules.

98+% of all LSRs assessed per protocol are Grade 0 (none) or Grade 1 (mild), with the vast majority being Grade 0

Subject #04-017: Photograph Data

Baseline



CSFS=3
PSFS=3

12 Weeks Post Treatment



CSFS=0
PSFS=0

10xBio IP Summary

704 Family: Polidocanol for Adipolysis

US, EP, CA, CN: Methods of reducing adipose tissue with 0.5% W/V to about 2.0% W/V polidocanol	US, AU, CA: Methods of reducing adipose tissue with 14+ day treatments w/o co-solvent	Pending
US, AU: Pharmaceutical formulation comprising up to about 5% W/V polidocanol	CA: Injectable polidocanol pharmaceutical formulation up to 5% polidocanol	CN, CA: Injectable polidocanol pharmaceutical formulation with 2%-5% polidocanol & use thereof
US, CN, CA, AU: Methods of reducing adipose tissue w/ 14+ day trmts. w/ polidocanol w/ solvent	CN: Polidocanol pharmaceutical formulation with 6%-10% polidocanol	
US, EP, CA: Pharmaceutical formulation comprising 0.5%-2% W/V polidocanol	Pending	
KR: Pharmaceutical formulation comprising 0.1%-2% W/V polidocanol	Pending	
JP: Pharmaceutical formulation comprising 0.5%-5% W/V polidocanol	EP: Use of formulation comprising up to 5% W/V polidocanol in 14+ day treatments w/o cosolvent	
JP, CA: Pharmaceutical formulation comprising 6%-10% W/V polidocanol	Pending	TBD

Issued | Pending | Planned

Summary

- **Best-in-class pharmaceutical body contouring product**
  - Superior efficacy and tolerability relative to current products
  - Areas of treatment expanded beyond submental contouring
- **Reduced development risk, time, and cost**
  - Novel formulation of polidocanol; long history safety; being developed under 505(b)2 pathway
- **Phase 3 ready in 2024**
- **Strong partner in select Asian countries**
- **Strong intellectual property position**
  - 12 issued patents covering formulation and method of use US, EU, CA, AU, JP, KR, CN.
- **Experienced leadership by dermatology industry veterans**
  - John Dobak, MD – past CEO, DermTech, Inc. (NASDAQ: DMTK); Dan Piacquadio, MD – CEO, Therapeutics, Inc.


Thank You